Research programme: ion channel modulators - Icagen, Inc.
Latest Information Update: 04 Nov 2017
At a glance
- Originator Icagen; University of California at Los Angeles
- Developer Icagen, Inc.
- Class
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors; TRPA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Neuropathic pain; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA